Lucid Diagnostics (NASDAQ: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), has announced a peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer...
Lucid Diagnostics (NASDAQ: LUCD) announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO. With more than 25 years of strategic and operational experience across...
Lucid Diagnostics (NASDAQ:LUCD) announced positive results from its clinical validation study of EsoGuard Esophageal DNA test on samples collected from patients with Barrett’s Esophagus (BE) and esophageal...
Analysts for BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics (NASDAQ:LUCD) with “buy” ratings and price targets of $14 and $18, respectively. The stock closed at $9.52 on Oct. 5. Lucid recently...